This message contains images. If you don't see images, click here to view.
Click here to advertise in this news brief.




Text Version  RSS  Subscribe  Unsubscribe  Archive  Media Kit October 10, 2014
Home    About AST    Education    Meetings & Events    Public Policy    Contact Us  

 

SOCIETY NEWS

Register for Upcoming Webinars: WTC Highlights and Changes in Healthcare
AST
WTC 2014 Clinical Highlights webinar on Tuesday, Oct. 21 from 2-3 p.m. EST. Register today at www.myAST.org/T3 - free for AST members. Presented by Pierre-Alain Clavien, MD, PhD, Christian Oberkofler, MD, and Thomas Muller, MD, PhD of the University of Zurich. Whether you missed the World Transplant Congress or simply did not have time to catch all of the sessions, attend this webinar and get the important clinical highlights from the meeting.

Kidney Allocation System Changes: Strategies to Improve Recipient Readiness and Reduce Disparities webinar on Tuesday, Nov. 4 from 2-3 p.m. EST. Register today at www.myAST.org/T3 - free for AST members.

Changes in the Health Care Environment and Transplantation webinar on Wednesday, Nov. 12, 2014 from 2-3 p.m. EST. Register today at www.myAST.org/business - free for AST members. Presented by Jon Friedman of Optum, Thomas Hamilton of CMS, and Patricia Martin of WellPoint, Inc. Understand changes in the healthcare environment and the effect of the ACA on transplantation.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article




Uniform donor risk interview forms available
AST
Interview forms optimized for obtaining medical history, behavioral risk, and travel information for a donor of organs and/or tissues, including ocular tissue, are now available. The forms were finalized by the DRAI Stakeholder Review Group, experts representing donation and transplantation organizations and government agencies. 
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


UPCOMING EVENTS IN TRANSPLANTATION


There is still time to register for the ESOT + AST Joint Meeting
AST
Personalized Transplantation: From New Diagnostics to New Therapeutics
Oct. 17-19, 2014
Madrid, Spain

Long-term graft and patient survival are the key issues in transplantation. Outcomes are affected by individual immune risk and co-morbidities, as well as gender and race. The time is now to focus on improving outcomes through personalized medicine and finding the optimal combination of immunosuppressive drugs in the right dose for each patient. Register now to attend this focused meeting on personalized transplantation. Join the ESOT and AST in beautiful Madrid, Spain as together we explore:
  • New Options to Improve Immunosuppressive Therapy Belatacept, Anti CD40 trial (ASKP1240), Anti- IL-6 and Tacrolimus formulations
  • Novel Diagnostics
    Donor DNA - Biomarker of Graft Injury, In vivo Live Imaging of the Immune Response and Tolerance Profile
  • Novel Targets for Immunosuppression
    B-cells, Plasma Cells and Complement
  • Personalized Medicine: Technique and Technology
    Sequencing for TCR Repertoire, Pharmacogenetics, Epigenetics and Mixed Chimerism
  • Cellular Strategies to Optimize Long Term Outcomes
    T-regs, Mesenchymal Cells, Facilitator Cells
Click here to learn more about this enlightening meeting, or view the full program.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article




Submit your basic, clinical, and translational abstracts by Oct. 31
The Cutting Edge of Transplantation
Immunity and Inflammation: Engineering Cell, Gene, and Drug Therapies

AST
Feb. 5-7, 2015
Sheraton Wild Horse Pass – Chandler, Arizona

The AST is now accepting abstracts for the Cutting Edge of Transplantation meeting. Don’t miss out on the opportunity to share your research with experts in transplantation. Submit your basic, clinical or translational abstract by Oct. 31. The AST will award a limited number of Young Innovator Award travel grants to the highest scoring abstracts submitted by emerging professionals in transplantation.

Click here to register for CEOT 2015 and take advantage of early registration discounted rates! Or, learn more about this engaging meeting and view the preliminary program here.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


COMMITMENT TO CARE
Raptor's mission is to develop and commercialize life-altering therapeutics that treat rare, debilitating, and often fatal diseases.
LEARN MORE
Advertise here!

To find out how to feature your company in the AST eNewsletter and other advertising opportunities, Contact Tom Crist at 972-402-7724.
MORE


ASN Kidney Week early program on transplantation
AST
Hotel Reservation Deadline is Oct. 14, 2014
In recent years, there have been important advances in the field of kidney transplantation that will impact the care of the kidney transplant recipient. ASN, in cooperation with AST, has developed an early program preceding Kidney Week that provides an interactive, case-based overview of exciting advances in kidney transplantation, with a focus upon specific populations, complications, and ethical issues. Nephrologists with an interest in transplantation, transplant physicians, and trainees in the nephrology are encouraged to attend this program. Get full program details and register here.

Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


TRANSPLANT NEWS


Impact of the lung allocation score on survival beyond 1 year
American Journal of Transplantation
Implementation of the lung allocation score (LAS) in 2005 led to transplantation of older and sicker patients without altering 1-year survival. However, long-term survival has not been assessed and emphasizing the 1-year survival metric may actually sustain 1-year survival while not reflecting worsening longer-term survival. Therefore, we assessed overall and conditional 1-year survival; and the effect of crossing the 1-year threshold on hazard of death in three temporal cohorts: historical (1995–2000), pre-LAS (2001–2005) and post-LAS (2005–2010).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


PRODUCT SHOWCASE
  UCLA Immunogenetics Center

The UCLA Immunogenetics Center (UIC) provides comprehensive testing for organ and tissue transplantation. Transplant testing has a long history at UCLA. HLA typing was pioneered here in the 1960's. The development of the microcytoxicity test in 1964 marked the beginning of international testing and standardization of HLA typing. The UCLA Immunogenetics Center has retained its leadership position in HLA research, and in the development of accompanying diagnostic testing. MORE
 


Risk of metabolic complications in kidney transplantation after conversion to mTOR inhibitor: A systematic review and meta-analysis
American Journal of Transplantation
Mammalian target of rapamycin (mTOR) inhibitors have been used in transplantation with the hope of minimizing calcineurin inhibitor (CNI)-induced nephrotoxicity. However, mTOR inhibitors are also associated with a range of side effects, including metabolic complications. We aimed to determine the risks of metabolic complications after the conversion from CNI to mTOR inhibitor postkidney transplant. A systematic search in PubMed up to September 2013 identified nine relevant trials (a total of 2323 patients).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Denatured class I human leukocyte antigen antibodies in sensitized kidney recipients: Prevalence, relevance, and impact on organ allocation
Transplantation
Single antigen flow beads assays may overestimate sensitization because of the detection of supposedly irrelevant antibodies recognizing denatured class I human leukocyte antigens (HLAs).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Impact of broader sharing on the transport time for deceased donor livers
Liver Transplantation
Recent allocation policy changes have increased the sharing of deceased donor livers across local boundaries, and sharing even broader than this has been proposed as a remedy for persistent geographic disparities in liver transplantation. It is possible that broader sharing may increase cold ischemia times (CITs) and thus harm recipients. We constructed a detailed model of transport modes (car, helicopter, and fixed-wing aircraft) and transport times between all hospitals, and we investigated the relationship between the transport time and the CIT for deceased donor liver transplants.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE




Acute liver allograft antibody-mediated rejection: An inter-institutional study of significant histopathological features
Liver Transplantation
Acute antibody-mediated rejection (AMR) occurs in a small minority of sensitized liver transplant recipients. Although histopathological characteristics have been described, specific features that could be used (1) to make a generalizable scoring system and (2) to trigger a more in-depth analysis are needed to screen for this rare but important finding. Toward this goal, we created training and validation cohorts of putative acute AMR and control cases from 3 high-volume liver transplant programs; these cases were evaluated blindly by 4 independent transplant pathologists.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


Hepatic artery and biliary complications in liver transplant recipients undergoing pretransplant transarterial chemoembolization
Liver Transplantation
Liver transplantation (LT) is the treatment of choice for patients with cirrhosis and hepatocellular carcinoma (HCC) not amenable to resection. Locoregional therapies for HCC are often used to reduce tumor burden, bridge patients to LT, and down-stage HCC so that patients are eligible for LT. We hypothesized that prior endovascular antitumor therapy may increase the risk of hepatic artery (HA) and biliary complications after LT. The aim of this study was to compare HA and biliary complications in LT recipients with HCC who received transarterial chemoembolization (TACE) before LT with complications in LT recipients with HCC who did not receive TACE before LT.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article
READ MORE


TRENDING ARTICLES
Missed last week's issue? See which articles your colleagues read most.

    Demethylation of the TSDR is a marker of squamous cell carcinoma in transplant recipients (American Journal of Transplantation)
Influence of recipient age on deceased donor kidney transplant outcomes in the expanded criteria donor era (Clinical Transplantation)
Neutrophil-to-lymphocyte ratio predicts mortality in patients listed for liver transplantation (Liver International)
Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma (American Journal of Transplantation)

Don't be left behind. Click here to see what else you missed.
 



AST eNews

Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Julie Bernhard, Executive Editor, 469.420.2647  
Contribute news


This edition of the AST eNews was sent to ##Email##. To unsubscribe, click here.

Recent issues
Oct. 3, 2014
Sept. 26, 2014
Sept. 19, 2014
Sept. 12, 2014






7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063